freepatentsonline.com

Tall fescue endophyte E34

Tue, 05 Jan 2010 08:00:00 EST

A tall fescue variety known as BE9301A which is inoculated with endophyte E34 is provided. Also provided is the endophyte E34. Methods of using the grass plant, seed, and endophyte are also provided. In particular examples, BE9301A is suitable for use in forage pastures due to the low amounts of alkaloids present.

Composition and wipe for reducing viscosity of viscoelastic bodily fluids

Tue, 05 Jan 2010 08:00:00 EST

The present invention provides a topical composition for application to the perianal and/or labial areas of the skin which helps prevent viscoelastic fluids, such as menses and feces, from attaching to the skin and aids in the reducing the viscoelastic properties of the fluid so that the fluid can flow into absorbent articles. The composition contains at least one viscoelastant material and at least one an anti-adherent material. the composition may be applied with a wipe, including mitts and gloves, a solid stick composition, an aerosol dispenser, a pump spray, a trigger spray, a squeeze bottle, as a foam, as a cream, as an ointment, as a salve, as a gel, as a wash or as a lotion. In addition, absorbent articles, such as pads or pants, diapers and the like may also be used as a means to transfer the composition to the skin.

PEGylated TNF-�� variant proteins

Tue, 05 Jan 2010 08:00:00 EST

The present invention relates to the use of simulation technology to rationally optimize the locations and sizes of attached polymeric moieties for modification of therapeutic proteins and the proteins generated from this method.

Hydroxyapatite grafted fumarate based macromers for biodegradable composites

Tue, 05 Jan 2010 08:00:00 EST

A composition is disclosed which comprises (i) a macromer prepared by reacting an unsaturated diacid having a carbon-carbon double bond and a saturated diacid, and (ii) a bioactive ceramic grafted to the macromer. In one embodiment, the unsaturated diacid having a carbon-carbon double bond is fumaric acid, the saturated diacid is compatible with fumaric acid and poly(propylene fumarate) such as succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid and mixtures thereof, and the bioactive ceramic is hydroxyapatite. In another embodiment, hydroxyapatite is grafted with a biodegradable and crosslinkable macromer comprising silane units alternating with furnarate and adipate units.

Methods of enhancing functioning of the large intestine

Tue, 05 Jan 2010 08:00:00 EST

The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases.

Molecular determinants of myeloma bone disease and uses thereof

Tue, 05 Jan 2010 08:00:00 EST

To identify molecular determinants of lytic bone disease in multiple myeloma, the expression profiles of ˜12,000 genes in CD138-enriched plasma cells from newly diagnosed multiple myeloma patients exhibiting no radiological evidence of lytic lesions (n=28) were compared to those with ≧3 lytic lesions (n=47). Two secreted WNT signaling antagonists, soluble frizzled related protein 3 (SFRP-3/FRZB) and the human homologue of Dickkopf-1 (DKK1), were expressed in 40 of 47 with lytic bone lesions, but only 16 of 28 lacking bone lesions (P<0.05). DKK1 and FRZB were not expressed in plasma cells from 45 normal bone marrow donors or 10 Waldenstrom's macroglobulinemia, a related plasma cells malignancy that lacks bone disease. These data indicate that these factors are important mediators of multiple myeloma bone disease, and inhibitors of these proteins may be used to block bone disease.

Compositions and methods for the prevention and control of insulin-induced hypoglycemia

Tue, 05 Jan 2010 08:00:00 EST

Pharmaceutical composition comprising both insulin and glucagon can be administered to control and treat diabetes while reducing or eliminating the risk of insulin-induced hypoglycemia.

Zinc-containing sustained-release composition, its preparation, and method for producing the same

Tue, 05 Jan 2010 08:00:00 EST

With a simple and high-yield production method, a zinc-containing sustained-release composition capable of stabilizing a physiologically active protein or peptide, typically G-CSF by precipitation and retaining drug efficacy for several days in a living body owing to its sustained releasability is provided. Concretely, a zinc-containing sustained-release composition produced by forming a precipitate by mixing a physiologically active protein or peptide, a water-soluble zinc salt, a water-soluble carbonate and/or a water soluble phosphate aqueous solution. The zinc-containing sustained-release composition may be administered as a zinc-containing sustained preparation by adding a pharmaceutically acceptable additive as is necessary.

Method for making heteromultimeric polypeptides

Tue, 05 Jan 2010 08:00:00 EST

The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method involves introducing a protuberance at the interface of a first polypeptide and a corresponding cavity in the interface of a second polypeptide, such that the protuberance can be positioned in the cavity so as to promote heteromultimer formation and hinder homomultimer formation. “Protuberances” are constructed by replacing small amino acid side chains from the interface of the first polypeptide with larger side chains (e.g. tyrosine or tryptophan). Compensatory “cavities” of identical or similar size to the protuberances are created in the interface of the second polypeptide by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). The protuberance and cavity can be made by synthetic means such as altering the nucleic acid encoding the polypeptides or by peptide synthesis.

Detergent composition containing a cationised silicone delivery system

Tue, 05 Jan 2010 08:00:00 EST

A cleansing cosmetic composition comprising; i) a cationized silicon delivery system selected from one or more of a) a cationized fatty alkyl silicone copolymer; b) a cationized dimethiconol complex and c) a cationized high viscosity lower alkyl silicone fluid with or without cationized silicone gum blend; and ii) detergent active. Also disclosed is a cationized silicone delivery system comprising: a) 15-50 parts of a cationized fatty alkyl silicone copolymer; b) 5-50 parts of a cationized dimethiconol complex; and c) 1-50 parts of a cationized high viscosity lower alkyl silicone fluid with cationized silicone gum blend.

Lactic acid bacteria and their cellular components inducing immunoregulatory function, and method of obtaining the same

Tue, 05 Jan 2010 08:00:00 EST

To provide a microorganism and an ingredient thereof that contribute to prevention and treatment of immune diseases including allergy, autoimmune diseases and inflammatory bowel diseases (e.g., large-intestinal ulcer), a method of effectively selecting the microorganism, and a method of efficiently inducing immunoregulatory cells that play an important role on maintaining immunological homeostasis using the microorganism or the ingredient thereof. The present invention provides a Lactococcus and an ingredient thereof which induce production of IL-10 from mammalian dendritic or spleen cells, a method of obtaining the microorganism or the ingredient thereof by co-culturing a microorganism such as Lactococcus strains with mammalian dendritic or spleen cells to select a microbial cell having a high IL-10 production ability, a method of selecting the microorganism or the ingredient thereof by co-culturing an intestinal epithelial cell with a microorganism such as the lactic acid bacteria and selecting the cells on the basis of a caspase-1 activity and the ability of inducing the production of IL-18, and a food product or material and an animal feeding stuff or medical and pharmaceutical products which contain the lactic acid bacteria as an effective ingredient.

Process of preparing a biodegradable polymer using an enzyme catalyst and a biodegradable polymer prepared through the process

Tue, 05 Jan 2010 08:00:00 EST

Disclosed is a process of preparing a biodegradable polymer using an enzyme catalyst and a biodegradable polymer prepared through the process. The process includes polycondensing a polyhydric alcohol monomer having a secondary hydroxyl functional group and an acid monomer having a dicarboxylic group in the presence of the enzyme catalyst. Since the biodegradable polymer according to the present invention is polymerized using an enzyme in the course of the polycondensation, it is easily prepared and friendly to nature, and it is possible to control the molecular weight by varying the reaction time in the course of the polymerization. Thus, the biodegradable polymer is usefully applied to control the dose of a drug in a drug release system and is useful as a supporter for regenerating a desired biological tissue of a patient in tissue engineering.

Methods of expressing gram-negative glycosaminoglycan synthase genes in gram-positive hosts

Tue, 05 Jan 2010 08:00:00 EST

The present invention relates to a Gram-negative glycosaminoglycan gene and methods of making and using same. The present invention relates to recombinant Gram-positive host cells containing a Gram-negative glycosaminoglycan synthase gene, and methods of producing glycosaminoglycans using such recombinant host cells.

Process for the intracellular over-production of streptokinase using genetically engineered strain of E. coli

Tue, 05 Jan 2010 08:00:00 EST

An improved process for the production of streptokinase using a genetically engineered strain of Escherichia coli which overproduces streptokinase intracellularly and more particularly, the overall process disclosed herein, concerns with an improvement in the fermentative production of streptokinase using an optimized growth medium mainly comprised of simple salts and trace-elements; thus, in principal, the present process constitutes an improved and more economical means for the production of streptokinase which may be useful in thrombolytic therapy.

Device and method for rapidly determining the effectiveness of sterilization or disinfection processes

Tue, 05 Jan 2010 08:00:00 EST

A device and a method for rapidly determining the effectiveness of sterilization or disinfection processes are provided. The method involves contacting a biological indicator containing a known number of live spores to a sterilization or disinfection process. When the spores are killed, the minerals in the spores are released. Water is contacted with the dead spores to form an aqueous solution. A parameter related to the concentration of a mineral in the aqueous solution is measured. The effectiveness of the germicidal process is determined from the parameter and the initial number of spores in the biological indicator. Measuring the parameter by measuring the conductivity of the aqueous solution is particularly effective and sensitive.

High throughput pharmaceutical screening using drosophila

Tue, 05 Jan 2010 08:00:00 EST

High throughput drug screening assay methods and related apparatus are described. Wild-type Drosophila are raised in multi-well microtiter plates on a growth medium having a high level of a sugar such as glucose. The high sugar diet during development induces screenably distinct characteristics in the wild-type Drosophila . Compounds that putatively modify the screenably distinct characteristic are tested by feeding to the Drosophila embryos, and determining whether the compound modifies the screenably distinct characteristic induced by the high sugar growth medium. The assay methods and related articles of composition can also be used to assay toxicity of candidate compounds.

Methods for targeting and killing glioma cells

Tue, 05 Jan 2010 08:00:00 EST

A diagnostic technique for matching anti-cancer peptide drugs to the molecular profiles of individual cancer tumors, and a method using the technique for a patient-specific treatment of tumors in mammals. This strategy matches anti-cancer peptide drugs to the molecular profiles of individual tumors, and includes the development of two banks, both of which use the same targeting peptides. Targeting peptides are identified using biopsies or other tissue materials from multiple cancer patients and placed into two banks. For a bank of probes, targeting peptides are linked to a label such as a fluorescent or a radioisotope. For a bank of drugs, targeting peptides are linked to a cytotoxic peptide to form a “targeting peptide drug”. Peptide probes are used to establish molecular profiles of individual tumors. Based on these molecular profiles, a patient-specific combination of targeting drugs from the bank of peptide drugs is prepared and the patient is treated. Any currently used cytotoxic agent that can be linked to targeting peptides may be used in place of cytotoxic peptides.

Screening methods for the identification of inhibitors of human immunodeficiency virus (HIV) viral protein R (Vpr) binding to the adenine nucleotide translocator (ANT)

Tue, 05 Jan 2010 08:00:00 EST

The invention is directed to the induction of mitochondrial membrane permeabilization via the physical and functional interaction of the HIV-1 Vpr protein with the mitochondrial inner membrane protein ANT (adenine nucleotide translocator, also called adenine nucleotide translocase or ADP/ATP carrier). Reagents and methods for inducing and/or inhibiting the binding of Vpr to ANT, mitochondrial membrane permeabilization, and apoptosis are provided.

Antibodies to protein markers associated with bone marrow stem cell differentiation into early progenitor dendritic cells

Tue, 05 Jan 2010 08:00:00 EST

A novel cytosolic 58 kd phosphoprotein induced during bone marrow stem cell (BM) differentiation into dendritic cells (DC) during in vitro cultivation with the cytokine GM-CSF by addition of antisera to an 82 kd BM cell surface protein generating cultivatable dendritic progenitor cells (DP). Genes, methods for preparing them as well as early DP have been provided. Potential uses/advantages lie in the study of BM differentiation and innate immunity due to stimulatory/inhibitory DC, contribution of (BM) and DP to inflammation during infection and carcinogenesis, tumor promotion/regression, identification of BM-derived blood cells, T-cell activation/regulation/tolerance and inflammation.

Chewing gum and confectionery compositions containing a stain removing complex, and methods of making and using the same

Tue, 05 Jan 2010 08:00:00 EST

A composition in the form of a chewing gum composition or a confectionery composition containing a stain removing complex of a stain removing agent and a cyclodextrin compound and methods of preparing and using the same to remove stains from dental material including teeth.

Synergistic composition for the treatment of diabetes mellitus

Tue, 05 Jan 2010 08:00:00 EST

A synergistic composition for the treatment of diabetes in a subject in need thereof, comprising Trigonelline of concentration ranging between 20 to 30%, amino acids of concentration ranging between 20 to 60%, and soluble fiber of concentration ranging between 10 to 60%, optionally along with pharmaceutically acceptable additives, a process thereof and also, a method of treating diabetes.

Nutritional composition for controlling blood sugar level

Tue, 05 Jan 2010 08:00:00 EST

A nutritional composition for controlling blood sugar level comprising a protein, a lipid and a carbohydrate, wherein energy percentages supplied by the protein, lipid and carbohydrate are 10 to 25%, 20 to 35% and 40 to 60%, respectively; and oleic acid in the lipid energy percentage is 60 to 90% and palatinose and/or trehalulose in the carbohydrate energy percentage is 60 to 100%. The composition is useful as an oral or tube feeding nutrient for nutritional management or blood sugar level control of patients suffering from diabetes and glucose intolerance, or for obesity prevention, a therapeutic diet, a diet for diabetic patients at home, an obesity preventive diet or a food with health claims.

Process and product for inhibiting or preventing bacterial infections

Tue, 05 Jan 2010 08:00:00 EST

A pharmacologically effective mixture of a polymyxin composition and a hop composition having a synergistic effect on bacteria greater than the antibacterial effect of those compositions administered separately.

Preparation and application of transhintotalphenolic acid

Tue, 05 Jan 2010 08:00:00 EST

A process for preparing tanshintotalphenolic acid and the use of the product are disclosed. The process comprises: tanshin is hot-extracted with water, the extract is separated and refined by polyamide column and macroporous adsorption resin column, and lyophilized to obtain tanshintotalphenolic acid. The yield of the final end product is more than 4 percent based on the amount of crude drug and the content of totalphenolic acid is more than 80 percent. The tanshintotalphenolic acid obtained can be used as the medicine for preventing and treating cerebrovascular and cardiovascular diseases and so on.

Anti-anal fistula composition and process for its manufacture

Tue, 05 Jan 2010 08:00:00 EST

The composition and process for preparing an anti-anal fistula composition which comprises providing a predetermined effective amount of natural substances of the genera Safflower, Notoginseng Radix, Lightyellow Sophora, Elecampane Redix, Rumex , Pine Resin, Sassafras Tree, Glycyrrhizae Radix, Testudinis Carapax, Rhei Rhizoma, Ephedrae Herba, Natrii Sulfas, Menthae Herba, Pasoniae Radix, Acontii Tuber, Corni Fructus, Gypsum, and Pelladendri Radix in an aqueous medium to form an initial mixture, extracting the initial mixture with water at a temperature of about 65°-75° C. for 1-2 hours to produce an aqueous mixture, filtering the aqueous mixture to produce a filtrate, and evaporating the filtrate to a moisture content of 30% to produce an extract which can be used as a treatment for hemorrhoid diseases including anal fistula.

Methods and compositions for maintaining or enhancing feeding characteristics in post-receiving stressed animals

Tue, 05 Jan 2010 08:00:00 EST

The present invention relates to methods and compositions for maintaining or enhancing feeding characteristics of post-receiving stressed animals using a saponin composition. In an embodiment, the invention includes a method for increasing feed intake of an animal after a post-receiving stressful event comprising administering an effective amount of a composition comprising saponins to the animal. In an embodiment, the invention includes a method for increasing weight gain of an animal after a post-receiving stressful event comprising administering an effective amount of a composition comprising saponins to the animal.

Anti-bacterial plant compositions

Tue, 05 Jan 2010 08:00:00 EST

The invention provides a pharmaceutical composition which comprises a pharmaceutical carrier and at least one compound selected from the group consisting of cobaltocene-octamethyl, stigmastan- 3,5 -diene, galoxolide, benzyl salicylate, eucalyptol, and α-pinene. Also provided is a method of preparing a composition having antimicrobial activity comprising extracting a plant material in an organic solvent, contacting the extracted material to a chromatographic column, and eluting from the chromatographic column with a mobile polar phase to obtain a composition. The plant material is from Mammea Americana, Marchantaceae polymorpha , or Callistemon citrinus . Also provided is a method of inhibiting the growth of a mycobacterium, comprising administering a composition comprising a carrier and at least one compound selected from among cobaltocene-octamethyl, stigmastan, 3,5 -diene, friedelin, galoxolide, benzyl salicylate, eucalyptol, and α-pinene.

Plasma cryoprecipitate substantially free of plasminogen

Tue, 05 Jan 2010 08:00:00 EST

A method for specifically removing or isolating plasmin(ogen) or plasmin in presence of fibrinogen from a mixture containing plasmin(ogen) or plasmin by contacting the mixture with a rigid amino acid wherein the amino group of the amino acid and the carboxylic group of the amino acid are about 6-8 Angstroms, preferably about 7 Angstroms apart and the rigid amino acid is covalently bound to the support via the amino group of the amino acid.

Method of encapsulating an active substance

Tue, 05 Jan 2010 08:00:00 EST

The invention provides a method of encapsulating an active substance in an interpolymer complex, to make an encapsulated product in particulate form. The method comprises forming a mixture of a supercritical fluid, an interpolymer complex and an active substance and then causing or allowing the interpolymer complex to encapsulate the active substance. The encapsulated product is then separated from the supercritical fluid and, if necessary, the product is subjected to size reduction to ontain particles in which the active substance is encapsulated by the interpolymer complex.

Digestible and volume adjustable multi medication delivery device

Tue, 05 Jan 2010 08:00:00 EST

A volume-adjustable device for the delivery of multiple medications to a subject, the device comprising multiple medication elements; an outer containment means having at least one open end into which the medication elements are removeably inserted; and a closure means removeably and adjustably inserted into at least one end of the outer containment means is disclosed.

Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules

Tue, 05 Jan 2010 08:00:00 EST

The present invention relates to novel cationic lipids, transfection agents, microparticles, nanoparticles, and short interfering nucleic acid (siNA) molecules. The invention also features compositions, and methods of use for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity in a subject or organism. Specifically, the invention relates to novel cationic lipids, microparticles, nanoparticles and transfection agents that effectively transfect or deliver biologically active molecules, such as antibodies (e.g., monoclonal, chimeric, humanized etc.), cholesterol, hormones, antivirals, peptides, proteins, chemotherapeutics, small molecules, vitamins, co-factors, nucleosides, nucleotides, oligonucleotides, enzymatic nucleic acids, antisense nucleic acids, triplex forming oligonucleotides, 2,5-A chimeras, dsRNA, allozymes, aptamers, decoys and analogs thereof, and small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules, to relevant cells and/or tissues, such as in a subject or organism. Such novel cationic lipids, microparticles, nanoparticles and transfection agents are useful, for example, in providing compositions to prevent, inhibit, or treat diseases, conditions, or traits in a cell, subject or organism. The compositions described herein are generally referred to as formulated molecular compositions (FMC) or lipid nanoparticles (LNP).

Acid-sensitive compounds, their preparation and uses

Tue, 05 Jan 2010 08:00:00 EST

Novel acid-sensitive compounds comprising a cyclic ortho-ester that is acid-sensitive, and their salts, and comprising at least one hydrophilic substituent. These compounds are useful, for example, for forming conjugates (liposomes, complexes, nanoparticles and the like) with biologically active substances and releasing them into cellular tissues or compartments whose pH is acidic, or as nonionic surfactant for stabilizing particles encapsulating a biologically active substance and then destabilizing them in acid medium, or alternatively as a vector covalently linked to a therapeutic molecule so as to release said therapeutic molecule into the cellular tissues or compartments whose pH is acidic.

Isolated species of Steinernematid nematode and methods of white grub control therewith

Tue, 05 Jan 2010 08:00:00 EST

An isolated Steinernematid nematode of the species Steinernema scarabaei (ATCC accession No. PTA-6988) is provided which is entomopathogenic to the larvae of scarab beetles, e.g., Japanese beetle ( Popillia japonica ), oriental beetles ( Exomala (= Anomala ) orientalis ), European chafer ( Rhizotrogus majalis ), Asiatic garden beetle ( Maladera castanea ), masked chafers ( Cyclocephala spp.), and May/June beetles ( Phyllophaga spp). A biopesticide composition is provided which comprises an insecticidally effective amount of Steinernema scarabaei . Biopesticide compositions are described which, in addition to Steinernema scarabaei , further comprise at least one neonicotinoid insecticide, e.g., imidacloprid. Methods are provided for controlling the larvae of at least one species of scarab beetle comprising applying a biopesticide composition to the locus of the larvae wherein the composition comprises an insecticidally effective amount of an isolated entomopathogenic nematode of the species Steinernema scarabaei.

Antimicrobial coatings for treatment of surfaces in a building setting and method of applying same

Tue, 05 Jan 2010 08:00:00 EST

Antimicrobial coatings to protect surfaces and a method of applying such a coating are disclosed. An antimicrobial coating may be applied to a surface, such as the interior surface of a building's exterior wall. The interior surface must be accessed, and then an antimicrobial coating is provided and applied. The antimicrobial coating includes an inorganic antimicrobial additive and a colloidal polymeric medium. The inorganic antimicrobial additive may be silver, platinum, gold, palladium, copper, zinc, boron, or a compound of any of those elements. By including an ultraviolet tracer or color dye additive in the coating, it is possible to detect the coating at any time, provided that the surface is accessed.

Immunological adjuvant compositions

Tue, 05 Jan 2010 08:00:00 EST

The present invention is directed to novel adjuvant compositions, which target the cellular and/or humoral arms of immunity. According to an embodiment of the invention, an oil-in-water adjuvant composition is provided that comprises: (a) water; (b) a metabolizable oil comprising at least one branched or unbranched long-chain hydrocarbon moiety; (c) a steroid; and (d) a saponin.

BASB027 proteins and genes from Moraxella catarrhalis, antigens, antibodies, and uses

Tue, 05 Jan 2010 08:00:00 EST

The invention provides BASB027 polypeptides and polynucleotides encoding BASB027 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.

Avirulent, immunogenic flavivirus chimeras

Tue, 05 Jan 2010 08:00:00 EST

Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural protein genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.

Dengue serotype 2 attenuated strain

Tue, 05 Jan 2010 08:00:00 EST

The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells. The invention further relates to a vaccine composition which comprises a VDV2 strain.

Dengue serotype 1 attenuated strain

Tue, 05 Jan 2010 08:00:00 EST

The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells. The invention further relates to a vaccine composition which comprises a VDV1 strain.

Intranasal immunization with detoxified lipooligosaccharide from nontypeable Haemophilus influenzae or Moraxella catarrhalis

Tue, 05 Jan 2010 08:00:00 EST

The invention relates to intranasal immunization with detoxified lipooligosaccharide from nontypeable Haemophilus influenzae or Moraxella catarrhalis.

Methods of inducing an immune response

Tue, 05 Jan 2010 08:00:00 EST

Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene products of a gene of FIG. 2 provide diagnostic, prognostic, prophylactic and/or therapeutic targets for cancer. A gene of FIG. 2 or fragment thereof, its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with a gene product of FIG. 2 can be used in active or passive immunization.

IL-32 monoclonal antibodies and uses thereof

Tue, 05 Jan 2010 08:00:00 EST

The present invention provides monoclonal antibodies specific for interleukin-32 (IL-32, previously referred to as “natural killer cell transcript 4” or “NK4”) and hybridomas secreting monoclonal antibodies specific for IL-32. Also provided are diagnostic methods and kits (e.g., ELISA, Western blot, etc.) which utilize monoclonal antibodies specific for IL-32.

Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders

Tue, 05 Jan 2010 08:00:00 EST

Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunomodulatory without conjugation to a therapeutic agents as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering the CD70 binding agents to a subject.

Compositions and methods for detecting cancer and for inhibiting metastasis

Tue, 05 Jan 2010 08:00:00 EST

The present invention relates to compositions and methods for detecting cancer (e.g., prostate cancer) and for inhibiting metastasis (e.g., associated with prostate cancer). In particular, the present invention provides methods of detecting vimentin expression and secretion and for characterizing cancer (e.g., prostate cancer). In addition, the present invention provides methods for inhibiting metastasis (e.g., of prostate cancer) via altering (e.g., inhibiting) vimentin expression and/or activity.

Immunotherapy of autoimmune disorders using antibodies which target B-cells

Tue, 05 Jan 2010 08:00:00 EST

Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal therapies. The antibodies may be bispecific antibodies which may be produced recombinantly as fusion proteins, or as hybrid, polyspecific antibodies.

Wound treatment utilizing collagenase and a phosphotidylcholine organogel

Tue, 05 Jan 2010 08:00:00 EST

The effect of the action of collagenase in treating lesions containing collagen or mixed fibrin clots (e.g., burns or ulcers) is improved by applying collagenase to the wound in combination with an organogel and a phosphatidylcholine, of which lecithin is a readily available source, particularly when the collagenase is first mixed and stored with that choline and an organic solvent and is subsequently mixed with a second individually stored formulation comprising a gel-forming agent and water, the two formulations individually having satisfactory shelf lives and the resultant mixture being applied to the lesion promptly after being formed.

Methods for inhibiting IL-TIF-induced proliferation of hematopoietic cells using the cytokine receptor Zcytor16

Tue, 05 Jan 2010 08:00:00 EST

Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.”

Keratinocyte-fibrocyte concomitant grafting for wound healing

Tue, 05 Jan 2010 08:00:00 EST

A system and method for dispersing living cells onto an area of a subject lacking normal, healthy skin, such as an open wound surface, to form three dimensional epithelial tissue is provided. The cells are dispersed using an air-jet sprayer after being suspended in a soluble media such as dextran. The cells may be dispersed directly onto the area or onto a tissue scaffold or synthetic substance that promotes wound healing.

Feeder layer and serum independent embryonic stem cells

Tue, 05 Jan 2010 08:00:00 EST

Undifferentiated primordial stem cells are manipulated to permit their long term growth in defined media lacking serum and feeder layer cells by shifting the apoptotic balance of the cells, through increasing the activity of Bcl-2 family anti-apoptotic proteins or decreasing the activity of Bcl-2 family pro-apoptotic proteins. In some embodiments of the invention, the Bcl family protein is Bcl-2. The ES cells sustain the characteristics of undifferentiated, pluripotent stem cells during long-term serum- and feeder layer cell-free conditions, including the ability to be expanded in vitro, but maintain their potential to differentiate into mature cell types.

Adjuvant viral particle

Tue, 05 Jan 2010 08:00:00 EST

The present invention relates to an immunogen-carrier having immunopotentiating or adjuvant properties. More particularly, the immunogen-carrier is a virus-like particle (VLP) from the family of potexvirus, and most particularly the papaya mosaic virus. The VLP produced by recombinant techniques is in fusion with one of its own proteins a protein immunogen. The above VLP and a protein or a protein extract from a viral, bacterial or parasital pathogen may be used as a vaccine.

Peptides for active anti-cytokine immunization

Tue, 05 Jan 2010 08:00:00 EST

Peptide of a size comprised between 5 and 40 amino acids, originating from a cytokine, in which at least one of its amino acids comprises at least one of its atoms separated by a distance d of less than 5 angströms from an atom of the receptor corresponding to said cytokine, the spacing d being evaluated on the basis of structural data, derivatives, immunogenic compounds comprising them, use of a peptide or peptide derivative or immunogenic compound for the preparation of a curative or preventative medicament intended for the treatment or prevention of diseases linked to an excess or to the presence of cytokines or for the treatment of an auto-immune disease and pharmaceutical compositions which contain at least one abovementioned peptide or peptide derivative or immunogenic compound as active ingredient.

Stimulating neutrophil function to treat inflammatory bowel disease

Tue, 05 Jan 2010 08:00:00 EST

Immune stimulatory amounts of hematopoietic colony stimulating factors are administered to patients with inflammatory bowel disease. The factors include G-CSF and GM-CSF. These factors induce and maintain remission of the disease and its manifestations, whether within the intestine or without.

Conformable solvent-based bandage and coating material

Tue, 05 Jan 2010 08:00:00 EST

Liquid hemostatic coating materials comprise a cyanoacrylate monomer and a solvent system comprising a volatile, non-reactive liquid that is non-stinging and non-irritating to a user. The material forms a coating or bandage in the form of a film that when applied and adhered to a surface or to the skin of a user inhibits the application surface from adhering to another surface.

Tooth whitening compositions and delivery systems therefor

Tue, 05 Jan 2010 08:00:00 EST

Stain-removing oral compositions, such as gum compositions are herein provided. The compositions include an orally acceptable carrier and a stain-removing anionic surfactant. The surfactant includes a fatty acid salt having at least one hydroxyl functionality. The fatty acid salt may be a salt of ricinoleic acid, and may be combined with a chelating agent and/or an abrasive. The chelating agent may be a polyphosphate and the abrasive may be a silica abrasive.

Chimeric, human and humanized anti-CSAp monoclonal antibodies

Tue, 05 Jan 2010 08:00:00 EST

The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.